Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials
Ánita Lawitschka(St Anna Children's Hospital), Peter Bader(Goethe University Frankfurt), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Jerry Stein(Schneider Children's Medical Center), Ulrike Pötschger(St Anna Children's Hospital), Franco Locatelli(Bambino Gesù Children's Hospital), Roland Meisel(Düsseldorf University Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Jacek Toporski(Skåne University Hospital), Marianne Ifversen(Copenhagen University Hospital), Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Marc Ansari(University of Geneva), Marc Bierings(University Medical Center Utrecht), Peter Švec(Comenius University Bratislava), Petr Sedláček(University Hospital in Motol), Tayfun Güngör, Helga Arnardottir, Jochen Büchner(Oslo University Hospital), Jean‐Hugues Dalle(Inserm)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
|Blood|2004|1.6k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738